Quarterly ResultAug 6, 2026, 04:16 PM
Xeris Biopharma Q2 Net Loss $(31.1)M Due to Debt Extinguishment
AI Summary
Xeris Biopharma reported a net loss of $(31.1) million for Q2 2026, primarily due to a $(30.8) million loss on debt extinguishment related to its 2028 Convertible Notes. Despite this, total revenue grew 28.7% to $92.1 million for the quarter, driven by strong Recorlev sales. The company's stockholders' equity shifted to a deficit of $(9.7) million as of June 30, 2026, following the debt-related activities.
Key Highlights
- Q2 2026 net loss was $(31.1) million, compared to $(1.9) million in Q2 2025.
- Recognized a $(30.8) million loss on debt extinguishment for 2028 Convertible Notes.
- Total revenue increased 28.7% to $92.1 million in Q2 2026.
- Recorlev product revenue surged 80.6% to $56.8 million in Q2 2026.
- Cash and cash equivalents rose to $121.7 million as of June 30, 2026.
- Stockholders' equity shifted to a deficit of $(9.7) million as of June 30, 2026.
- Settled 2028 Convertible Notes in July 2026 with 8.6 million shares and $23.0 million cash.
Price Impact
More from XERS